Bangladeshi generic version slashes rare disease drug’s price by 96%
Bangladeshi pharmaceutical company Beximco has launched a generic version of a triple combination therapy for a rare genetic disorder. US-based Vertex, which holds the patent for this therapy, charges $325,300 for a year’s treatment while the generic will slash the price by 96% to just $12,775 for adults and about $6,390 for a child per…